COMMUNIQUÉS West-GlobeNewswire

Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
20/07/2026
- Priority Review granted; PDUFA target action date set for January 21, 2027 - - Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion cohort of the DELIVER [...]
Daré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities
20/07/2026
President & CEO, Sabrina Martucci Johnson, to host interactive investor webcasts featuring corporate updates, commercial strategy and live Q&A SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. ( [...]
University of Szeged Pioneers First Robotic Cardiology Program in Hungary
20/07/2026
First Robotic Magnetic Navigation system installed in Hungary University of Szeged, led by Cardiology Chief Dr. Szili-Torok, expected to treat hundreds of patients annually with all forms of cardiac arrhythmia using [...]
Xanamem proof-of-concept trial demonstrating anti-depressant activity published in the British Journal of Psychiatry
20/07/2026
Ongoing Xanamem (emestedastat) Alzheimer’s disease pivotal trial progresses toward final results in November this year SYDNEY, July 20, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) today announces that [...]
Noom Launches 'Lose for Keeps' with Rebel Wilson, a New Campaign Making the Case That GLP-1 Medication and Healthy Habits Work Better Together
20/07/2026
PRINCETON, N.J., July 20, 2026 (GLOBE NEWSWIRE) -- Noom, the leading behavior change company, launched Lose for Keeps – a new integrated brand campaign featuring Rebel Wilson in her second year as the company’s Chief [...]
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
20/07/2026
WILMETTE, Ill., July 20, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with [...]
Positron Secures Multiple PET-CT Orders Amid Accelerating Shift to Cardiac PET
20/07/2026
BUFFALO, NY, July 20, 2026 (GLOBE NEWSWIRE) -- Positron Corporation ("Positron" or the "Company") (OTC: POSC), a leader in advanced molecular imaging technology and comprehensive PET imaging solutions, today announced [...]
Novo Nordisk A/S - share repurchase programme
20/07/2026
Bagsværd, Denmark, 20 July 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) [...]
DLH to Announce Fiscal 2026 Third Quarter Financial Results
20/07/2026
ATLANTA, July 20, 2026 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of science research and development, systems engineering and integration, and digital [...]
Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer
20/07/2026
Designation supports development in an estimated $1 billion market where there are no FDA-approved therapies for patients whose disease progresses following first-line standard of care therapy Third Fast Track [...]
TOMI Environmental and Carbonium Core Positioned To Play Key Role in The Onshoring of Essential Strategic Materials for Defense and Global Disinfection
20/07/2026
FREDERICK, Md., July 20, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ) (“TOMI”), the leader in decontamination equipment and services with its patented SteraMist ionized Hydrogen Peroxide ( [...]
Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion
20/07/2026
● As of July 18, 2026, net asset value (NAV 1 ) per share was $66.16 ● As of July 18, 2026, Enlivex held 79,550,593,122 RAIN tokens with a total value of approximately $1.1 billion 2 . Nes-Ziona, Israel, July 20, 2026 ( [...]
BrainsWay Announces Strategic Investment in Radial Health, Inc.
20/07/2026
BrainsWay continues to actively evaluate similar investments in leading North American mental health providers to raise awareness and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, July 20, 2026 ( [...]
Collegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in Boston
20/07/2026
New headquarters reflects Collegium's long-term vision and commitment to Massachusetts STOUGHTON, Mass., July 20, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) a leading biopharmaceutical [...]
CurePSP Awards Record Pathway and Pipeline Grants to Advance PSP and CBD Research
20/07/2026
NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- CurePSP has announced its largest grant cycle to date, awarding a record number of Pathway and Pipeline Grants to researchers across North America and Europe. The grants [...]
MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29
20/07/2026
MARIETTA, Ga., July 20, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second quarter ended June 30 [...]
Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering
20/07/2026
MOUNTAIN VIEW, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the [...]
INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform
20/07/2026
Commercial-Ready Manufacturing Now Supports Planned Phase 3 Confirmation Trial, and US, EU and UK Regulatory Submissions for Future Commercial Supply. Company Expresses Support for MHRA Draft Rare Disease Therapies [...]
Nouscom Selected for Oral Presentation on NOUS-209 Re-treatment and Long-Term Follow-Up in Lynch Syndrome Carriers at ESMO Congress 2026
20/07/2026
New data from the Phase 1b/2 trial of NOUS-209 in Lynch Syndrome (LS) carriers have been accepted for an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 NOUS-209 is an off-the-shelf [...]

Pages